Overview

Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency

Status:
Completed

Trial end date:
2017-12-28

Target enrollment:

Participant gender:

Summary

This study evaluated the safety and efficacy of sebelipase alfa in a broad population of participants with lysosomal acid lipase deficiency (LAL-D).

Phase:

Phase 2

Details

Lead Sponsor:

Alexion Pharmaceuticals